Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Rodman & Renshaw Initiates Coverage On Leap Therapeutics with Buy Rating, Announces Price Target of $8

Author: Benzinga Newsdesk | June 28, 2024 12:46pm

Rodman & Renshaw analyst Tony Butler initiates coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and announces Price Target of $8.

Posted In: LPTX